242 Wythe Ave #4, Brooklyn, NY 11249
1-090-1197-9528
office@ourbusiness.com

Marco Brughera

Marco Brughera

Marco Brughera is an accomplished executive with over 35 years of experience in R&D and General Management, focusing on Rare Diseases and Oncology in global pharmaceutical and biotech companies. Notably, he served as the Group CEO of Leadiant Biosciences from 2012 to 2021, leading the registration and launch of key products for Rare Diseases. Marco Brughera successfully turned the company around, enhancing profitability resulting in the sale of some assts for a value of about $2 billion.

Marco Brughera has extensive drug development, portfolio management, out-license experience.

His board memberships include Leadiant Biosciences Inc., Leadiant Biosciences Ltd and Fennec and past roles at Naicoms Exelead, Gentium, Soligenix, Lee’s Pharmaceutical, among others. He serves as a strategic advisor at Essetifin and Global Lead of the Rare Diseases business. His extensive global professional journey also includes leadership roles at Sigma-Tau, Nerviano Medical Sciences, Pfizer, Pharmacia, and Farmitalia Carlo Erba.